Drug intelligence / Profile preview

ARQ 171

Development stage: Discontinued
Lead developer: Merck
Modality: Small Molecules
Administration: Intravenous

Overview

ARQ 171 is a small molecule investigational drug that functions as an activator of the E2F1 pathway. It induces the expression of E2F transcription factor 1 (E2F1), thereby activating the E2F1-mediated checkpoint process, which is down-regulated in many cancer cells. By restoring E2F1 activity, ARQ 171 aims to selectively kill cancer cells by reactivating DNA damage response and checkpoint pathways, leading to apoptosis (programmed cell death) while sparing normal cells. The drug was developed for use in solid tumors but its clinical development has been discontinued[1][2][5][7].

Targets

E2F1 (E2F Transcription Factor 1)

Beyond the preview

Go deeper on ARQ 171.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARQ 171.

Explore the full profile